Frontlight ResearchEarly access
Head and neck cancer trials in Germany
35 of 51 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Frankfurt
- Age
- 18 years and over
- People
- 890 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - Phase 3Taking peopleJNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
- Where
- Giessen, Hanover, Jena, München, Rostock
- Age
- 60 years and over
- People
- 500 worldwide
- Run by
- Johnson & Johnson Enterprise Innovation Inc.
See details and how to joinNCT04892173 · EU 2024-520386-31-00 - Phase 1/2Taking peopleA Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
- Where
- Essen, Leipzig, Stuttgart
- Age
- 18 years and over
- People
- 287 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06385080 · EU 2023-508418-40-00 - Phase 3Taking peopleA Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- Where
- Bonn, Essen, Frankfurt Am Main, Giessen, Hanover, Leipzig, Regensburg, Rostock, Ulm
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07276399 · EU 2025-521917-24-00 - Phase 2/3Taking peopleFORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- Where
- Aachen, Berlin, Brunswick, Chemnitz, Dresden, Duesseldorf, Essen, Goettingen, Hanover, Karlsruhe, Mainz, Munich, Stuttgart, Ulm
- Age
- 18 years and over
- People
- 650 worldwide
- Run by
- Bicara Therapeutics
See details and how to joinNCT06788990 · EU 2024-519654-37-00 - Phase 2Not yet taking people in GermanyDB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- Where
- Frankfurt am Main, Giessen
- Age
- 18 years and over
- People
- 750 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00 - Phase 3Taking peopleA Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.
- Where
- Cologne, Frankfurt Am Main, Freiburg im Breisgau, Kiel, Tuebingen
- Age
- 18 years to 80 years
- People
- 150 worldwide
- Run by
- OncoZenge AB
See details and how to joinNCT07672236 · EU 2025-524386-24-00 - Phase 1/2Taking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Berlin, Dresden, Heidelberg, Heilbronn, Leipzig, Mainz, Muenster
- Age
- 18 years and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - Phase 2Not yet taking people in GermanySafety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP Trial
- Where
- Cologne, Greifswald, Hagen, Hamburg, Würzburg
- Age
- 18 years and over
- People
- 66 worldwide
- Run by
- University Hospital, Basel, Switzerland
See details and how to joinNCT07840456 - Phase 2Not yet taking people in GermanyA Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC
- Where
- Cologne, Giessen, Hamburg, Heidelberg, Kiel, Leipzig, Luebeck, Mannheim, Munich, Wuerzburg
- Age
- 18 years and over
- People
- 160 worldwide
- Run by
- Bicara Therapeutics
See details and how to joinNCT07807163 · EU 2026-526741-10-00 - Phase 3Not yet taking people in GermanyA Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
- Where
- Cologne, Leipzig, Münster
- Age
- 18 years and over
- People
- 260 worldwide
- Run by
- Corbus Pharmaceuticals Inc.
See details and how to joinNCT07768189 · EU 2026-527123-94-00 - Phase 1/2Taking peopleThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Where
- Augsburg, Essen, Frankfurt am Main, Hamburg, Heidelberg
- Age
- 12 years and over
- People
- 300 worldwide
- Run by
- PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750 - Phase 1Taking peopleStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Where
- Essen, Heidelberg, Herne, Jena, Nuertingen, Tuebingen
- Age
- 18 years and over
- People
- 1,394 worldwide
- Run by
- Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00 - Phase 3Taking peopleA Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
- Where
- Berlin, Erlangen, Essen, Freiburg im Breisgau, Greifswald, Hamburg, Hanover, Leipzig, Lübeck, München, Rostock, Tübingen, Ulm, Würzburg
- Age
- 18 years to 130 years
- People
- 1,145 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06129864 - Phase 2Taking peopleStudy of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
- Where
- Cologne, Frankfurt am Main, Gauting, Grosshansdorf, Hamburg, Heidelberg, Leipzig, Mainz, Muenster, Offenbach Am Main, Regensburg, Rheine
- Age
- 18 years to 64 years
- People
- 257 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06535607 · EU 2025-523947-36-00 - Phase 3Taking peopleRe-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC
- Where
- Berlin, Chemnitz, Darmstadt, Dresden, Erfurt, Erlangen, Frankfurt Am Main, Giessen, Hamburg, Hanover, Herne, Homburg, Kiel, Leipzig, Mainz, Muenster, Munich, Regensburg, Rostock, Straubing, Stuttgart, Tuebingen, Ulm
- Age
- 18 years and over
- People
- 214 worldwide
- Run by
- Universität des Saarlandes
See details and how to joinNCT07026474 · EU 2024-520264-33-00 - Phase 1/2Taking peopleSafety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma
- Where
- Berlin, Cologne, Giessen, Goettingen, Hamburg
- Age
- 18 years and over
- People
- 110 worldwide
- Run by
- Nykode Therapeutics ASA
See details and how to joinNCT06016920 · EU 2022-503055-26-00 - Phase 1/2Taking peopleA Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Where
- Dresden, Essen, Frankfurt, Ulm, Würzburg
- Age
- 18 years and over
- People
- 1,109 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT04895709 - No phaseTaking peopleApp-based Recording and Optimization of the Nutritional Status in Patients With Head and Neck Tumors During and After Radio(Chemo)Therapy
- Where
- Erlangen
- Age
- 18 years and over
- People
- 148
- Run by
- University of Erlangen-Nürnberg Medical School
See details and how to joinNCT06367257 - Phase 1Taking peopleA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Where
- Berlin
- Age
- 18 years and over
- People
- 714 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00 - Phase 1/2Taking peopleFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Where
- Erlangen
- Age
- 18 years and over
- People
- 880 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT05768139 · EU 2023-504807-94-00 - Phase 2Taking peopleA Phase II Randomized Clinical Trial Comparing Two Cycles Versus Four Cycles of Combination Therapy with Cetuximab, Avelumab, Cisplatin, and Docetaxel in Patients with Recurrent Metastatic Head and Neck Cancer - AVETUX-HN
- Where
- Aachen, Berlin, Essen, Hanover, Stuttgart
- Age
- 18 years and over
- People
- 126
- Run by
- Charite Universitaetsmedizin Berlin KöR
See details and how to join2025-521738-27-00 - Phase 1/2Taking peopleAfatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
- Where
- Hanover
- Age
- 18 years and over
- People
- 25 worldwide
- Run by
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
See details and how to joinNCT06648096 · EU 2024-511477-29-00 - Phase 3Active, not recruitingA Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
- Where
- Augsburg, Berlin, Erlangen, Essen, Giessen, Hamburg, Straubing
- Age
- 18 years and over
- People
- 864 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT06256588 · EU 2023-508613-17-00 - Phase 3Taking peopleA Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
- Where
- Berlin, Freiburg im Breisgau, Munich
- Age
- 18 years and over
- People
- 410 worldwide
- Run by
- AVEO Pharmaceuticals, Inc.
See details and how to joinNCT06064877 · EU 2023-505606-42-00